Logo image of ALSMA.PA

SMAIO SA (ALSMA.PA) Stock Fundamental Analysis

EPA:ALSMA - Euronext Paris - Matif - FR0014005I80 - Common Stock - Currency: EUR

3.5  0 (0%)

Fundamental Rating

3

ALSMA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 55 industry peers in the Health Care Equipment & Supplies industry. While ALSMA seems to be doing ok healthwise, there are quite some concerns on its profitability. ALSMA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALSMA had negative earnings in the past year.
In the past year ALSMA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ALSMA reported negative net income in multiple years.
In the past 5 years ALSMA reported 4 times negative operating cash flow.
ALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M

1.2 Ratios

The Return On Assets of ALSMA (-14.21%) is worse than 61.82% of its industry peers.
Looking at the Return On Equity, with a value of -22.35%, ALSMA is doing worse than 61.82% of the companies in the same industry.
Industry RankSector Rank
ROA -14.21%
ROE -22.35%
ROIC N/A
ROA(3y)-2.24%
ROA(5y)-17.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSMA.PA Yearly ROA, ROE, ROICALSMA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 400

1.3 Margins

ALSMA's Gross Margin of 88.45% is amongst the best of the industry. ALSMA outperforms 92.73% of its industry peers.
In the last couple of years the Gross Margin of ALSMA has declined.
ALSMA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-4.68%
ALSMA.PA Yearly Profit, Operating, Gross MarginsALSMA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

5

2. Health

2.1 Basic Checks

ALSMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALSMA has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for ALSMA has been reduced compared to 5 years ago.
ALSMA has a worse debt/assets ratio than last year.
ALSMA.PA Yearly Shares OutstandingALSMA.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
ALSMA.PA Yearly Total Debt VS Total AssetsALSMA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

ALSMA has an Altman-Z score of 2.79. This is not the best score and indicates that ALSMA is in the grey zone with still only limited risk for bankruptcy at the moment.
ALSMA has a better Altman-Z score (2.79) than 69.09% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that ALSMA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.31, ALSMA is in line with its industry, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 2.79
ROIC/WACCN/A
WACC7.6%
ALSMA.PA Yearly LT Debt VS Equity VS FCFALSMA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

2.3 Liquidity

ALSMA has a Current Ratio of 5.08. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 5.08, ALSMA belongs to the best of the industry, outperforming 89.09% of the companies in the same industry.
ALSMA has a Quick Ratio of 4.25. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
ALSMA's Quick ratio of 4.25 is amongst the best of the industry. ALSMA outperforms 92.73% of its industry peers.
Industry RankSector Rank
Current Ratio 5.08
Quick Ratio 4.25
ALSMA.PA Yearly Current Assets VS Current LiabilitesALSMA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

6

3. Growth

3.1 Past

ALSMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.01%.
Looking at the last year, ALSMA shows a decrease in Revenue. The Revenue has decreased by -4.09% in the last year.
ALSMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 114.98% yearly.
EPS 1Y (TTM)-24.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-209.52%
Revenue 1Y (TTM)-4.09%
Revenue growth 3Y83.56%
Revenue growth 5Y114.98%
Sales Q2Q%-44.7%

3.2 Future

Based on estimates for the next years, ALSMA will show a very strong growth in Earnings Per Share. The EPS will grow by 51.68% on average per year.
The Revenue is expected to grow by 32.39% on average over the next years. This is a very strong growth
EPS Next Y-70.21%
EPS Next 2Y55.74%
EPS Next 3Y51.68%
EPS Next 5YN/A
Revenue Next Year2.79%
Revenue Next 2Y38.75%
Revenue Next 3Y34.09%
Revenue Next 5Y32.39%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALSMA.PA Yearly Revenue VS EstimatesALSMA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M
ALSMA.PA Yearly EPS VS EstimatesALSMA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALSMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 33.98, the valuation of ALSMA can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as ALSMA.
ALSMA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.10.
Industry RankSector Rank
PE N/A
Fwd PE 33.98
ALSMA.PA Price Earnings VS Forward Price EarningsALSMA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSMA.PA Per share dataALSMA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ALSMA's earnings are expected to grow with 51.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.74%
EPS Next 3Y51.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALSMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SMAIO SA

EPA:ALSMA (3/7/2025, 7:00:00 PM)

3.5

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.30M
Analysts84.44
Price Target5.92 (69.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.85%
Revenue NY rev (3m)0.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 33.98
P/S 3.73
P/FCF N/A
P/OCF N/A
P/B 2.28
P/tB 3.11
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)0.1
Fwd EY2.94%
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.94
BVpS1.53
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.21%
ROE -22.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.45%
FCFM N/A
ROA(3y)-2.24%
ROA(5y)-17.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-4.68%
F-Score1
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.63%
Cap/Sales 25.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.08
Quick Ratio 4.25
Altman-Z 2.79
F-Score1
WACC7.6%
ROIC/WACCN/A
Cap/Depr(3y)92.26%
Cap/Depr(5y)157.16%
Cap/Sales(3y)36.32%
Cap/Sales(5y)86.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-209.52%
EPS Next Y-70.21%
EPS Next 2Y55.74%
EPS Next 3Y51.68%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.09%
Revenue growth 3Y83.56%
Revenue growth 5Y114.98%
Sales Q2Q%-44.7%
Revenue Next Year2.79%
Revenue Next 2Y38.75%
Revenue Next 3Y34.09%
Revenue Next 5Y32.39%
EBIT growth 1Y-100.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.81%
EBIT Next 3Y53.44%
EBIT Next 5YN/A
FCF growth 1Y-170.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-137.93%
OCF growth 3YN/A
OCF growth 5YN/A